Robert K. Brooner, Ph.D.

Robert K. Brooner, Ph.D.
Robert K. Brooner, Ph.D.
Senior Research Scientist
Professor Emerita of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine
Special Assistant to CEO of Man Alive Treatment Center

Ph.D., Alliant University, Clinical Psychology
rkbrooner@aol.com
Phone: 410-837-3977
Fax: 410-752-4218
Research Interests

Dr. Brooner was the principal architect of the Addiction Treatment Services and Center for Addiction and Pregnancy at the Johns Hopkins Bayview Medical Center, along with leading the development, implementation, and oversight of the first outpatient substance use disorder treatment program for the NIH-NIDA Intramural Research Center in Baltimore, MD.  He is the PI, Co-PI and Co-Investigator of many NIH and other grant-making research awards, and author of over 150 peer-reviewed publications reporting their findings.  Dr. Brooner joined Johns Hopkins School of Medicine in 1983 as an Intern in Medical Psychology and advanced to tenured professor in 1999, retiring July 2021 with the title of Emeritus Professor of Psychiatry and Behavioral Sciences. His research interests during a successful 38+ year career focused on the assessment and treatment of substance use disorder. This work included the development of specialized treatment programs for pregnant women (Center for Addiction and Pregnancy), treatment of opioid use disorder patients with other psychiatric problems, evaluations of combinations of pharmacologic and behavioral treatments for substance use disorder, and the development, implementation and testing of a combination and adaptive treatment approach for these patients and problems. He is perhaps best known in the field for his experience and expertise in the development of highly successful treatment programs that provided natural laboratories for the development and testing of new interventions and service delivery models of care. In collaboration with Dr. Maxine Stitzer and Dr. George Bigelow, Dr. Brooner established the Mid Atlantic Node of the National Institute on Drug Abuse Clinical Trials Network (CTN), serving as the original PI of that project. His current work continues to advance our understanding and treatment of opioid and other substance use problems, including recent studies evaluating the relationships between cerebral blood flow and substance use, use of electronic pillboxes to enhance the availability and safety of methadone take-home doses, and the use of community pharmacies to administer and dispense methadone via prescription from OTP prescribers to community pharmacies. He will continue much of this work in his new role at Friends Research Institute.

Selected Publications
Ward, K. M., Falade-Nwulia, O., Moon, J., Sutcliffe, C. G., Brinkley, S., Haselhuhn, T., Katz, S., Herne, K., Arteaga, L., Mehta, S. H., Latkin, C., Brooner, R. K., & Sulkowski, M. S. (2021). Non-adherence to LDV/SOF did not predict SVR in a randomized controlled trial of HIV/HCV coinfected persons who use drugs. Journal of Infectious Diseases.
Dunn KE, Brooner RK, Clark MR (2014). Severity and interference of chronic pain in methadone-maintained outpatients. Pain Medicine 15, 1540-1548.
Brooner RK, Kidorf MS, King VL, Peirce J, Neufeld K. Stoller K (2013). Managing psychiatric comorbidity within versus outside of methadone treatment settings: A randomized and controlled evaluation. Addiction 108, 1942-1951.
Kidorf M, Brooner RK, Gandotra N, Antoine D, King VL, Peirce J, Ghazarian S (2013). Reinforcing integrated psychiatric service attendance in an opioid-agonist program: A randomized and controlled trial Drug and Alcohol Dependence. 133, 30-36.
King VL, Brooner RK, Peirce JM, Kolodner K, Kidorf MS (2013). A randomized trial of web-based videoconferencing for substance abuse counseling Journal of Substance Abuse Treatment 46, 36-42.
Brooner RK, Kidorf MS, Disney L, King VL, Kolodner K, Neufeld, K (2007). Comparing adaptive stepped care and monetary voucher interventions in the treatment of opioid dependent outpatients. Drug and Alcohol Dependence 14-23.
Brooner RK, Neufeld K, Disney E, Kidorf MS, King VL (2007). Antisocial personality in patients with substance use disorders: Evaluation and treatment. In: Substance Dependence and Co-occurring Psychiatric Disorders: Best Practices for Diagnosis and Treatment (eds: Nunes N, Selzer J, Levounis, P). Civic Research Institute.
Brooner RK, Kidorf MS, King VL, Stoller, KB, Peirce JM, Bigelow GE, Kolodner K (2004). Behavioral contingencies improve counseling attendance in an adaptive treatment model. Journal of Substance Abuse Treatment 27(3), 223-232.
Brooner RK, Kidorf MS (2002). Using behavioral reinforcement to improve methadone treatment participation. Science and Practice Perspectives 1, 38-46.
Schwartz RP, Brooner RK, Montoya ID, Currens M, Hayes M (1999). A 12-year follow-up of a methadone medical maintenance program. American Journal on Addictions 8, 293-299.
Brooner RK, Kidorf MS, King VL, Beilenson P, Svikis D, Vlahov D (1998). Drug abuse treatment success among needle exchange participants. Public Health Reports 113(1), 129-139.
Brooner RK, Kidorf MS, King VL, Stoller KB (1998). Preliminary evidence of improved treatment response in antisocial drug abusers. In Special Issue: Recent perspectives on antisocial problems in drug abusers (ed. RK Brooner). Drug and Alcohol Dependence 49, 249-260.
Brooner RK, King VL, Kidorf MS, Schmidt CW, Bigelow GE (1997). Psychiatric and substance use comorbidity in treatment-seeking opioid abusers. Archives of General Psychiatry 54, 71-80.
Silverman K, Higgins ST, Brooner RK, Montoya ID, Cone EJ, Schuster CR, Preston KL (1996). Sustained cocaine abstinence in intravenous drug abusers through voucher-based reinforcement therapy. Archives of General Psychiatry 53, 409-415.
Brooner RK, Herbst JH, Schmidt CW, Bigelow GE, Costa PT (1993). Antisocial personality disorder among drug abusers: Relations to other personality diagnoses and the five-factor model of personality. Journal of Nervous and Mental Disease 181(5), 313-319.
Brooner RK, Schmidt CW, Felch LJ, Bigelow GE (1992). Antisocial behavior of intravenous drug abusers: Implications for the diagnosis of antisocial personality disorder American Journal of Psychiatry 149(4), 482-487.